{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:00Z","timestamp":1786981500095,"version":"build-2736575974"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001512","name":"National Brain Tumor Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001512","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Meningiomas are generally considered \u201cbenign,\u201d however, these tumors can demonstrate variability in behavior and a surprising aggressiveness with elevated rates of recurrence. The advancement of next-generation molecular technologies have led to the understanding of the genomic and epigenomic landscape of meningiomas and more recent correlations with clinical characteristics and behavior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on a thorough review of recent peer-reviewed publications (PubMed) and edited texts, we provide a molecular overview of meningiomas with a focus on relevant clinical implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The identification of specific somatic driver mutations has led to the classification of several major genomic subgroups, which account for more than 80% of sporadic meningiomas, and can be distinguished using noninvasive clinical variables to help guide management decisions. Other somatic genomic modifications, including non-coding alterations and copy number variations, have also been correlated with tumor characteristics. Furthermore, epigenomic modifications in meningiomas have recently been described, with DNA methylation being the most widely studied and potentially most clinically relevant. Based on these molecular insights, several clinical trials are currently underway in an effort to establish effective medical therapeutic options for meningioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As we enhance our multiomic understanding of meningiomas, our ability to care for patients with these tumors will continue to improve. Further biological insights will lead to additional progress in precision medicine for meningiomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-021-03874-9","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T13:58:19Z","timestamp":1638280699000},"page":"205-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications"],"prefix":"10.1007","volume":"156","author":[{"given":"Stephanie M.","family":"Robert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaurey","family":"Vetsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushii","family":"Nadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Vasandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Youngblood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelan","family":"Marianayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Zeynep","family":"Erson-Omay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"G\u00fcnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-5874","authenticated-orcid":false,"given":"Jennifer","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"issue":"5","key":"3874_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3322\/caac.21693","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL, Barnholtz-Sloan JS (2021) Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin 71(5):381\u2013406","journal-title":"CA Cancer J Clin"},{"issue":"12 Suppl 2","key":"3874_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neuro Oncol 22(12 Suppl 2):iv1\u2013iv96","journal-title":"Neuro Oncol"},{"issue":"4","key":"3874_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3171\/jns.1992.77.4.0616","volume":"77","author":"H Maier","year":"1992","unstructured":"Maier H, Ofner D, Hittmair A, Kitz K, Budka H (1992) Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 77(4):616\u2013623","journal-title":"J Neurosurg"},{"issue":"6","key":"3874_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803\u2013820","journal-title":"Acta Neuropathol"},{"issue":"1","key":"3874_CR5","doi-asserted-by":"publisher","first-page":"11220","DOI":"10.1038\/s41598-020-68177-x","volume":"10","author":"MV Corniola","year":"2020","unstructured":"Corniola MV, Lemee JM, Meling TR (2020) Histological transformation in recurrent WHO grade I meningiomas. Sci Rep 10(1):11220","journal-title":"Sci Rep"},{"issue":"5","key":"3874_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3171\/2019.8.JNS191266","volume":"135","author":"MW Youngblood","year":"2019","unstructured":"Youngblood MW, Duran D, Montejo JD, Li C, Omay SB, Ozduman K, Sheth AH, Zhao AY, Tyrtova E, Miyagishima DF, Fomchenko EI, Hong CS, Clark VE, Riche M, Peyre M, Boetto J, Sohrabi S, Koljaka S, Baranoski JF, Knight J, Zhu H, Pamir MN, Avsar T, Kilic T, Schramm J, Timmer M, Goldbrunner R, Gong Y, Bayri Y, Amankulor N, Hamilton RL, Bilguvar K, Tikhonova I, Tomak PR, Huttner A, Simon M, Krischek B, Kalamarides M, Erson-Omay EZ, Moliterno J, Gunel M (2019) Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg 135(5):1345\u20131354","journal-title":"J Neurosurg"},{"issue":"8","key":"3874_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"},{"issue":"6","key":"3874_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/neuros\/nyy121","volume":"83","author":"K Kerr","year":"2018","unstructured":"Kerr K, Qualmann K, Esquenazi Y, Hagan J, Kim DH (2018) Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease. Neurosurgery 83(6):1107\u20131118","journal-title":"Neurosurgery"},{"issue":"10","key":"3874_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ng.3651","volume":"48","author":"VE Clark","year":"2016","unstructured":"Clark VE, Harmanci AS, Bai H, Youngblood MW, Lee TI, Baranoski JF, Ercan-Sencicek AG, Abraham BJ, Weintraub AS, Hnisz D, Simon M, Krischek B, Erson-Omay EZ, Henegariu O, Carrion-Grant G, Mishra-Gorur K, Duran D, Goldmann JE, Schramm J, Goldbrunner R, Piepmeier JM, Vortmeyer AO, Gunel JM, Bilguvar K, Yasuno K, Young RA, Gunel M (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48(10):1253\u20131259","journal-title":"Nat Genet"},{"issue":"6123","key":"3874_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077\u20131080","journal-title":"Science"},{"issue":"3","key":"3874_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45(3):285\u2013289","journal-title":"Nat Genet"},{"issue":"2","key":"3874_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0294-180","volume":"6","author":"MH Ruttledge","year":"1994","unstructured":"Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP et al (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6(2):180\u2013184","journal-title":"Nat Genet"},{"issue":"49","key":"3874_CR13","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.18632\/oncotarget.27841","volume":"11","author":"AA Nazem","year":"2020","unstructured":"Nazem AA, Ruzevick J, Ferreira MJ Jr (2020) Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies. Oncotarget 11(49):4544","journal-title":"Oncotarget"},{"issue":"1","key":"3874_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00174-7","volume":"8","author":"S Agnihotri","year":"2017","unstructured":"Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, Mamatjan Y, Klironomos G, Gonen L, Au K (2017) Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun 8(1):1\u20137","journal-title":"Nat Commun"},{"key":"3874_CR15","doi-asserted-by":"crossref","unstructured":"Zhao AY, Youngblood MW, Erson-Omay EZ, Moliterno J, Gunel M (2020) The genomic landscape of meningiomas. In: Meningiomas. Springer, pp 35\u201355","DOI":"10.1007\/978-3-030-59558-6_4"},{"issue":"2","key":"3874_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11060-021-03819-2","volume":"154","author":"L Jin","year":"2021","unstructured":"Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J (2021) Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. J Neurooncol 154(2):237\u2013246","journal-title":"J Neurooncol"},{"key":"3874_CR17","first-page":"1","volume":"1","author":"TP Gupte","year":"2020","unstructured":"Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J (2020) Clinical and genomic factors associated with seizures in meningiomas. J Neurosurg 1:1\u201310","journal-title":"J Neurosurg"},{"issue":"4","key":"3874_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cancergen.2015.02.003","volume":"208","author":"MJ Smith","year":"2015","unstructured":"Smith MJ (2015) Germline and somatic mutations in meningiomas. Cancer Genet 208(4):107\u2013114","journal-title":"Cancer Genet"},{"issue":"2","key":"3874_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00401-020-02247-2","volume":"141","author":"P Sievers","year":"2021","unstructured":"Sievers P, Sill M, Blume C, Tauziede-Espariat A, Schrimpf D, Stichel D, Reuss DE, Dogan H, Hartmann C, Mawrin C (2021) Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathol 141(2):281\u2013290","journal-title":"Acta Neuropathol"},{"key":"3874_CR20","doi-asserted-by":"publisher","first-page":"14433","DOI":"10.1038\/ncomms14433","volume":"8","author":"AS Harmanci","year":"2017","unstructured":"Harmanci AS, Youngblood MW, Clark VE, Coskun S, Henegariu O, Duran D, Erson-Omay EZ, Kaulen LD, Lee TI, Abraham BJ, Simon M, Krischek B, Timmer M, Goldbrunner R, Omay SB, Baranoski J, Baran B, Carrion-Grant G, Bai H, Mishra-Gorur K, Schramm J, Moliterno J, Vortmeyer AO, Bilguvar K, Yasuno K, Young RA, Gunel M (2017) Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun 8:14433","journal-title":"Nat Commun"},{"issue":"3","key":"3874_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00401-013-1093-x","volume":"125","author":"DE Reuss","year":"2013","unstructured":"Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J (2013) Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125(3):351\u2013358","journal-title":"Acta Neuropathol"},{"issue":"36","key":"3874_CR22","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1038\/s41388-018-0328-7","volume":"37","author":"J Boetto","year":"2018","unstructured":"Boetto J, Apra C, Bielle F, Peyre M, Kalamarides M (2018) Selective vulnerability of the primitive meningeal layer to prenatal Smo activation for skull base meningothelial meningioma formation. Oncogene 37(36):4955\u20134963","journal-title":"Oncogene"},{"issue":"3","key":"3874_CR23","first-page":"345","volume":"19","author":"J Boetto","year":"2017","unstructured":"Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M (2017) SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro Oncol 19(3):345\u2013351","journal-title":"Neuro Oncol"},{"issue":"4","key":"3874_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/path.4427","volume":"234","author":"MJ Smith","year":"2014","unstructured":"Smith MJ, Wallace AJ, Bennett C, Hasselblatt M, Elert-Dobkowska E, Evans LT, Hickey WF, Van Hoff J, Bauer D, Lee A (2014) Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol 234(4):436\u2013440","journal-title":"J Pathol"},{"key":"3874_CR25","doi-asserted-by":"crossref","unstructured":"Gill CM, Loewenstern J, Rutland JW, Arib H, Pain M, Umphlett M, Kinoshita Y, McBride RB, Bederson J, Donovan M, Sebra R, Fowkes M, Shrivastava RK (2021) SWI\/SNF chromatin remodeling complex alterations in meningioma. J Cancer Res Clin Oncol","DOI":"10.1093\/neuros\/nyaa447_817"},{"issue":"5","key":"3874_CR26","doi-asserted-by":"publisher","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","volume":"108","author":"F Sahm","year":"2016","unstructured":"Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T (2016) TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst 108(5):djv377","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"3874_CR27","first-page":"5995","volume":"59","author":"K Ueki","year":"1999","unstructured":"Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T (1999) Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59(23):5995\u20135998","journal-title":"Cancer Res"},{"issue":"10","key":"3874_CR28","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/NEN.0b013e3181ba3952","volume":"68","author":"D Gabeau-Lacet","year":"2009","unstructured":"Gabeau-Lacet D, Engler D, Gupta S, Scangas GA, Betensky RA, Barker FG 2nd, Loeffler JS, Louis DN, Mohapatra G (2009) Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. J Neuropathol Exp Neurol 68(10):1155\u20131165","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Suppl 1","key":"3874_CR29","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/neuonc\/noy178","volume":"21","author":"S Suppiah","year":"2019","unstructured":"Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H (2019) Molecular and translational advances in meningiomas. Neuro Oncol 21(Suppl 1):i4\u2013i17","journal-title":"Neuro Oncol"},{"issue":"4","key":"3874_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/jnen\/63.4.275","volume":"63","author":"K Lamszus","year":"2004","unstructured":"Lamszus K (2004) Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63(4):275\u2013286","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"3874_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11060-010-0342-2","volume":"99","author":"C Mawrin","year":"2010","unstructured":"Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99(3):379\u2013391","journal-title":"J Neurooncol"},{"issue":"3","key":"3874_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","volume":"133","author":"A Olar","year":"2017","unstructured":"Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DT, Pfister SM, Sulman EP, Aldape KD (2017) Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol 133(3):431\u2013444","journal-title":"Acta Neuropathol"},{"key":"3874_CR33","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3389\/fonc.2020.01382","volume":"10","author":"J Ma","year":"2020","unstructured":"Ma J, Hong Y, Chen W, Li D, Tian K, Wang K, Yang Y, Zhang Y, Chen Y, Song L (2020) High copy-number variation burdens in cranial meningiomas from patients with diverse clinical phenotypes characterized by hot genomic structure changes. Front Oncol 10:1382","journal-title":"Front Oncol"},{"issue":"1","key":"3874_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13039-019-0434-4","volume":"12","author":"S Hemmer","year":"2019","unstructured":"Hemmer S, Urbschat S, Oertel J, Ketter R (2019) Deletions in the 17q chromosomal region and their influence on the clonal cytogenetic evolution of recurrent meningiomas. Mol Cytogenet 12(1):1\u20138","journal-title":"Mol Cytogenet"},{"issue":"5","key":"3874_CR35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00401-018-1899-7","volume":"136","author":"TA Juratli","year":"2018","unstructured":"Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK (2018) DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome. Acta Neuropathol 136(5):779\u2013792","journal-title":"Acta Neuropathol"},{"issue":"21","key":"3874_CR36","doi-asserted-by":"publisher","first-page":"10596","DOI":"10.18632\/oncotarget.2517","volume":"5","author":"MS Abedalthagafi","year":"2014","unstructured":"Abedalthagafi MS, Merrill PH, Bi WL, Jones RT, Listewnik ML, Ramkissoon SH, Thorner AR, Dunn IF, Beroukhim R, Alexander BM (2014) Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget 5(21):10596","journal-title":"Oncotarget"},{"issue":"1","key":"3874_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4132\/jptm.2019.11.05","volume":"54","author":"YS Lee","year":"2020","unstructured":"Lee YS, Lee YS (2020) Molecular characteristics of meningiomas. J Pathol Transl Med 54(1):45","journal-title":"J Pathol Transl Med"},{"issue":"3","key":"3874_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11060-019-03333-6","volume":"145","author":"A Guyot","year":"2019","unstructured":"Guyot A, Duchesne M, Robert S, Lia AS, Derouault P, Scaon E, Lemnos L, Salle H, Durand K, Labrousse F (2019) Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma. J Neurooncol 145(3):449\u2013459","journal-title":"J Neurooncol"},{"issue":"3","key":"3874_CR39","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","volume":"140","author":"P Sievers","year":"2020","unstructured":"Sievers P, Hielscher T, Schrimpf D, Stichel D, Reuss DE, Berghoff AS, Neidert MC, Wirsching HG, Mawrin C, Ketter R, Paulus W, Reifenberger G, Lamszus K, Westphal M, Etminan N, Ratliff M, Herold-Mende C, Pfister SM, Jones DTW, Weller M, Harter PN, Wick W, Preusser M, von Deimling A, Sahm F (2020) CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 140(3):409\u2013413","journal-title":"Acta Neuropathol"},{"issue":"5","key":"3874_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00401-004-0911-6","volume":"108","author":"MJ Bello","year":"2004","unstructured":"Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso ME, Lomas J, de Campos JM, Kusak ME, Vaquero J, Isla A, Gutierrez M, Sarasa JL, Rey JA (2004) DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol 108(5):413\u2013421","journal-title":"Acta Neuropathol"},{"key":"3874_CR41","doi-asserted-by":"crossref","unstructured":"Shen L, Lin D, Cheng L, Tu S, Wu H, Xu W, Pan Y, Wang X, Zhang J, Shao A (2020) Is DNA methylation a ray of sunshine in predicting meningioma prognosis? Front Oncol 10","DOI":"10.3389\/fonc.2020.01323"},{"issue":"3","key":"3874_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10014-015-0221-9","volume":"32","author":"M Venza","year":"2015","unstructured":"Venza M, Visalli M, Beninati C, Catalano T, Biondo C, Teti D, Venza I (2015) Involvement of epimutations in meningioma. Brain Tumor Pathol 32(3):163\u2013168","journal-title":"Brain Tumor Pathol"},{"issue":"5","key":"3874_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.trsl.2012.05.007","volume":"160","author":"A Di Vinci","year":"2012","unstructured":"Di Vinci A, Brigati C, Casciano I, Banelli B, Borz\u00ec L, Forlani A, Ravetti GL, Allemanni G, Melloni I, Zona G (2012) HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. Transl Res 160(5):355\u2013362","journal-title":"Transl Res"},{"issue":"2","key":"3874_CR44","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/carcin\/bgr260","volume":"33","author":"Y Kishida","year":"2012","unstructured":"Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, Shinjo K, Saito K, Ando H, Ohka F (2012) Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 33(2):436\u2013441","journal-title":"Carcinogenesis"},{"issue":"1","key":"3874_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bbrc.2013.02.044","volume":"433","author":"H Ando","year":"2013","unstructured":"Ando H, Natsume A, Iwami K, Ohka F, Kuchimaru T, Kizaka-Kondoh S, Ito K, Saito K, Sugita S, Hoshino T (2013) A hypoxia-inducible factor (HIF)-3\u03b1 splicing variant, HIF-3\u03b14 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3\u03b14. Biochem Biophys Res Commun 433(1):139\u2013144","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3874_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11060-010-0411-6","volume":"103","author":"JA Kandenwein","year":"2011","unstructured":"Kandenwein JA, Park-Simon T-W, Schramm J, Simon M (2011) uPA\/PAI-1 expression and uPA promoter methylation in meningiomas. J Neurooncol 103(3):533\u2013539","journal-title":"J Neurooncol"},{"issue":"13","key":"3874_CR47","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1016\/j.celrep.2018.03.013","volume":"22","author":"HN Vasudevan","year":"2018","unstructured":"Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR (2018) Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. Cell Rep 22(13):3672\u20133683","journal-title":"Cell Rep"},{"key":"3874_CR48","doi-asserted-by":"crossref","unstructured":"Nassiri F, Wang JZ, Singh O, Karimi S, Dalcourt T, Ijad N, Pirouzmand N, Ng H-K, Saladino A, Pollo B (2021) Loss of H3K27me3 in meningiomas. Neuro-oncology","DOI":"10.1093\/neuonc\/noab036"},{"issue":"6","key":"3874_CR49","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00401-018-1844-9","volume":"135","author":"LM Katz","year":"2018","unstructured":"Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F (2018) Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 135(6):955\u2013963","journal-title":"Acta Neuropathol"},{"issue":"39","key":"3874_CR50","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/onc.2012.468","volume":"32","author":"N Kliese","year":"2013","unstructured":"Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E, Riek-Burchardt M, Angenstein F, Reifenberger G, Riemenschneider MJ (2013) miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 32(39):4712\u20134720","journal-title":"Oncogene"},{"key":"3874_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clineuro.2017.03.016","volume":"156","author":"S Katar","year":"2017","unstructured":"Katar S, Baran O, Evran S, Cevik S, Akkaya E, Baran G, Antar V, Hanimoglu H, Kaynar MY (2017) Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma. Clin Neurol Neurosurg 156:66\u201370","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"3874_CR52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/bpa.12110","volume":"24","author":"S Goutagny","year":"2014","unstructured":"Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M (2014) High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 24(2):184\u2013189","journal-title":"Brain Pathol"},{"issue":"11","key":"3874_CR53","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar GM, Santagata S (2017) BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol 19(11):1447\u20131456","journal-title":"Neuro Oncol"},{"issue":"4","key":"3874_CR54","first-page":"535","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT Jr, Cahill DP, Barker FG 2nd, Brastianos PK, Santagata S (2017) Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol 19(4):535\u2013545","journal-title":"Neuro Oncol"},{"key":"3874_CR55","doi-asserted-by":"publisher","first-page":"541928","DOI":"10.3389\/fonc.2020.541928","volume":"10","author":"Z Zador","year":"2020","unstructured":"Zador Z, Landry AP, Saha A, Cusimano MD (2020) Gene expression signatures identify biologically homogenous subgroups of grade 2 meningiomas. Front Oncol 10:541928","journal-title":"Front Oncol"},{"issue":"5","key":"3874_CR56","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/cancers13051113","volume":"13","author":"F Liu","year":"2021","unstructured":"Liu F, Qian J, Ma C (2021) MPscore: a novel predictive and prognostic scoring for progressive meningioma. Cancers 13(5):1113","journal-title":"Cancers"},{"issue":"5","key":"3874_CR57","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D, Jones DT, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18(5):682\u2013694","journal-title":"Lancet Oncol"},{"issue":"7","key":"3874_CR58","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Ng HK, Noushmehr H, Harter P, Baumgarten P, Weller M, Preusser M, Herold-Mende C, Tatagiba M, Tabatabai G, Sahm F, von Deimling A, M. International Consortium on, Zadeh G, Aldape KD (2019) DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol 21(7):901\u2013910","journal-title":"Neuro Oncol"},{"key":"3874_CR59","doi-asserted-by":"crossref","unstructured":"Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury A, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alexander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Bi WL (2021) A molecularly integrated grade for meningioma. Neuro-oncology","DOI":"10.14791\/btrt.2022.10.F-2747"},{"issue":"43","key":"3874_CR60","doi-asserted-by":"publisher","first-page":"21715","DOI":"10.1073\/pnas.1912858116","volume":"116","author":"AJ Patel","year":"2019","unstructured":"Patel AJ, Wan YW, Al-Ouran R, Revelli JP, Cardenas MF, Oneissi M, Xi L, Jalali A, Magnotti JF, Muzny DM, Doddapaneni H, Sebastian S, Heck KA, Goodman JC, Gopinath SP, Liu Z, Rao G, Plon SE, Yoshor D, Wheeler DA, Zoghbi HY, Klisch TJ (2019) Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc Natl Acad Sci USA 116(43):21715\u201321726","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7874","key":"3874_CR61","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, Macklin AM, Khan S, Singh O, Karimi S, Corona RI, Liu LY, Chen CY, Chakravarthy A, Wei Q, Mehani B, Suppiah S, Gao A, Workewych AM, Tabatabai G, Boutros PC, Bader GD, de Carvalho DD, Kislinger T, Aldape K, Zadeh G (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597(7874):119\u2013125","journal-title":"Nature"},{"issue":"5","key":"3874_CR62","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","volume":"23","author":"MW Youngblood","year":"2021","unstructured":"Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D, Montejo JD, Zhao A, Sheth A, Tyrtova E (2021) Associations of meningioma molecular subgroup and tumor recurrence. Neuro Oncol 23(5):783\u2013794","journal-title":"Neuro Oncol"},{"key":"3874_CR63","doi-asserted-by":"crossref","unstructured":"Hong CS, Moliterno J (2020) Surgical considerations for newly diagnosed meningiomas. In: Meningiomas. Springer, pp 75\u201396","DOI":"10.1007\/978-3-030-59558-6_6"},{"issue":"3","key":"3874_CR64","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","volume":"26","author":"T Graillon","year":"2020","unstructured":"Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyri\u00e8re H, Basset N, Autran D, Roche C, Kalamarides M (2020) Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin Cancer Res 26(3):552\u2013557","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3874_CR65","first-page":"48","volume":"3","author":"V Juric","year":"2020","unstructured":"Juric V, Murphy B (2020) Cyclin-dependent kinase inhibitors in brain cancer: Current state and future directions. Cancer Drug Resist 3(1):48\u201362","journal-title":"Cancer Drug Resist"},{"issue":"6","key":"3874_CR66","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2013.10.FOCUS13360","volume":"35","author":"S He","year":"2013","unstructured":"He S, Pham MH, Pease M, Zada G, Giannotta SL, Wang K, Mack WJ (2013) A review of epigenetic and gene expression alterations associated with intracranial meningiomas. Neurosurg Focus 35(6):E5","journal-title":"Neurosurg Focus"},{"key":"3874_CR67","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clineuro.2017.05.002","volume":"158","author":"V Galani","year":"2017","unstructured":"Galani V, Lampri E, Varouktsi A, Alexiou G, Mitselou A, Kyritsis AP (2017) Genetic and epigenetic alterations in meningiomas. Clin Neurol Neurosurg 158:119\u2013125","journal-title":"Clin Neurol Neurosurg"},{"key":"3874_CR68","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.humpath.2018.07.035","volume":"84","author":"T San-Miguel","year":"2019","unstructured":"San-Miguel T, Navarro L, Megias J, Munoz-Hidalgo L, Gil-Benso R, Roldan P, Lopez-Gines C, Cerda-Nicolas M (2019) Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur. Hum Pathol 84:105\u2013114","journal-title":"Hum Pathol"},{"issue":"2","key":"3874_CR69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5114\/fn.2020.96970","volume":"58","author":"S Samal","year":"2020","unstructured":"Samal S, Patnaik A, Sahu F, Purkait S (2020) Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice. Folia Neuropathol 58(2):133\u2013142","journal-title":"Folia Neuropathol"},{"key":"3874_CR70","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.biopha.2018.06.005","volume":"105","author":"H Xing","year":"2018","unstructured":"Xing H, Wang S, Li Q, Ma Y, Sun P (2018) Long noncoding RNA LINC00460 targets miR-539\/MMP-9 to promote meningioma progression and metastasis. Biomed Pharmacother 105:677\u2013682","journal-title":"Biomed Pharmacother"},{"key":"3874_CR71","doi-asserted-by":"publisher","first-page":"108718","DOI":"10.1016\/j.biopha.2019.108718","volume":"113","author":"T Li","year":"2019","unstructured":"Li T, Ren J, Ma J, Wu J, Zhang R, Yuan H, Han X (2019) LINC00702\/miR-4652\u20133p\/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt\/beta-catenin pathway. Biomed Pharmacother 113:108718","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3874_CR72","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/jcb.29423","volume":"121","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Yu R, Li Q, Li Y, Xuan T, Cao S, Zheng J (2020) SNHG1\/miR-556-5p\/TCF12 feedback loop enhances the tumorigenesis of meningioma through Wnt signaling pathway. J Cell Biochem 121(2):1880\u20131889","journal-title":"J Cell Biochem"},{"issue":"1","key":"3874_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-012-1038-6","volume":"112","author":"V Balik","year":"2013","unstructured":"Balik V, Srovnal J, Sulla I, Kalita O, Foltanova T, Vaverka M, Hrabalek L, Hajduch M (2013) MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas. J Neurooncol 112(1):1\u20138","journal-title":"J Neurooncol"},{"key":"3874_CR74","doi-asserted-by":"publisher","first-page":"579599","DOI":"10.3389\/fonc.2020.579599","volume":"10","author":"K Huntoon","year":"2020","unstructured":"Huntoon K, Toland AMS, Dahiya S (2020) Meningioma: a review of clinicopathological and molecular aspects. Front Oncol 10:579599","journal-title":"Front Oncol"},{"issue":"8","key":"3874_CR75","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/neuonc\/noab036","volume":"23","author":"F Nassiri","year":"2021","unstructured":"Nassiri F, Wang JZ, Singh O, Karimi S, Dalcourt T, Ijad N, Pirouzmand N, Ng HK, Saladino A, Pollo B, Dimeco F, Yip S, Gao A, Aldape KD, Zadeh G, M. International Consortium on (2021) Loss of H3K27me3 in meningiomas. Neuro Oncol 23(8):1282\u20131291","journal-title":"Neuro Oncol"},{"issue":"5","key":"3874_CR76","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1600-0404.2006.00590.x","volume":"113","author":"M Olivera","year":"2006","unstructured":"Olivera M, Martinez C, Molina JA, Alonso-Navarro H, Jimenez-Jimenez FJ, Garcia-Martin E, Benitez J, Agundez JA (2006) Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma. Acta Neurol Scand 113(5):322\u2013326","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"3874_CR77","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00401-018-1899-7","volume":"136","author":"TA Juratli","year":"2018","unstructured":"Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG 2nd, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK (2018) DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome. Acta Neuropathol 136(5):779\u2013792","journal-title":"Acta Neuropathol"},{"key":"3874_CR78","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3389\/fonc.2020.01491","volume":"10","author":"J Liu","year":"2020","unstructured":"Liu J, Xia C, Wang G (2020) Multi-omics analysis in initiation and progression of meningiomas: from pathogenesis to diagnosis. Front Oncol 10:1491","journal-title":"Front Oncol"},{"key":"3874_CR79","doi-asserted-by":"crossref","unstructured":"Weber RG et al (1997) Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Nat Acad Sci 94(26):14719\u201314724","DOI":"10.1073\/pnas.94.26.14719"}],"updated-by":[{"DOI":"10.1007\/s11060-021-03937-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000}}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03874-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03874-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03874-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T08:52:45Z","timestamp":1676019165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03874-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3874"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03874-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"24 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11060-021-03937-x","URL":"https:\/\/doi.org\/10.1007\/s11060-021-03937-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}